Phreesia’s (PHR) “Market Outperform” Rating Reaffirmed at JMP Securities

JMP Securities restated their market outperform rating on shares of Phreesia (NYSE:PHR) in a research note issued to investors on Thursday morning, Benzinga reports. They currently have a $30.00 target price on the stock.

Several other analysts have also recently commented on PHR. DA Davidson reiterated a buy rating and issued a $32.00 target price on shares of Phreesia in a report on Thursday. Needham & Company LLC reiterated a buy rating and issued a $29.00 target price on shares of Phreesia in a report on Thursday. Stephens reiterated an overweight rating and issued a $28.00 target price on shares of Phreesia in a report on Friday, May 31st. Truist Financial restated a buy rating and set a $29.00 price target on shares of Phreesia in a report on Monday, July 1st. Finally, Royal Bank of Canada restated a sector perform rating and set a $23.00 price target on shares of Phreesia in a report on Thursday. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $30.42.

Phreesia Stock Down 8.3 %

Shares of NYSE PHR opened at $23.55 on Thursday. The stock has a 50-day moving average price of $23.38 and a two-hundred day moving average price of $22.75. Phreesia has a 12 month low of $12.05 and a 12 month high of $29.16. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.03. The company has a market cap of $1.35 billion, a price-to-earnings ratio of -10.85 and a beta of 0.93.

Insider Transactions at Phreesia

In other news, CEO Chaim Indig sold 2,644 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $23.74, for a total transaction of $62,768.56. Following the transaction, the chief executive officer now directly owns 1,219,361 shares of the company’s stock, valued at $28,947,630.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Chaim Indig sold 2,644 shares of the stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $23.74, for a total value of $62,768.56. Following the completion of the sale, the chief executive officer now directly owns 1,219,361 shares of the company’s stock, valued at approximately $28,947,630.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Allison C. Hoffman sold 14,110 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $26.03, for a total value of $367,283.30. Following the completion of the sale, the general counsel now directly owns 121,003 shares of the company’s stock, valued at $3,149,708.09. The disclosure for this sale can be found here. Insiders have sold 29,337 shares of company stock valued at $736,750 over the last ninety days. 5.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. nVerses Capital LLC grew its stake in shares of Phreesia by 76.5% during the 2nd quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock worth $64,000 after acquiring an additional 1,300 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Phreesia by 5,462.3% during the 4th quarter. Russell Investments Group Ltd. now owns 3,838 shares of the company’s stock worth $89,000 after acquiring an additional 3,769 shares during the period. EntryPoint Capital LLC bought a new position in shares of Phreesia during the 1st quarter worth $169,000. Quadrature Capital Ltd bought a new position in shares of Phreesia during the 1st quarter worth $202,000. Finally, Lombard Odier Asset Management USA Corp bought a new position in shares of Phreesia during the 2nd quarter worth $202,000. Institutional investors own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.